Date: 17 November 2026

Regulatory Compliance Update

The inspection was conducted at the InvaGen manufacturing facility located in Hauppauge, Long Island, New York, USA from 19 October 2026 to 22 October 2026.

Via communication dated 17 November 2026, the USFDA has classified this inspection as No Action Indicated (NAI).

This communication follows the company's previous intimation regarding the inspection dated 23 October 2026.

KMP / Board / Auditor Changes

Not Specified

Dividend Declaration or Non-Declaration

Not Specified

Board Meeting Outcomes

Not Specified

Financial Results

Not Specified

Disinvestment / Strategic Actions

Not Specified

Other Operational / Legal / Strategic Disclosures

The disclosure confirms regulatory compliance status for the US manufacturing operations of InvaGen Pharmaceuticals Inc., a wholly owned subsidiary.